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Abstract
Background:  Ureaplasma urealyticum and  U. parvum have been associated with respiratory
diseases in premature newborns, but their role in the pathogenesis of the respiratory distress
syndrome (RDS) is unclear. The aim of this study was to detect, using molecular techniques, the
role of Mycoplasma spp. and Ureaplasma spp. in respiratory secretion and blood specimens of
preterm newborns with or without RDS and to evaluate the prevalence of perinatal U. urealyticum
or U. parvum infection. The influence of chemotherapy on the clinical course was also evaluated.
Methods: Tracheal aspirate or nasopharingeal fluid samples from 50 preterm babies with (24) or
without RDS (26) were analysed for detection of U. urealyticum and  U. parvum by culture
identification assay and PCR. Sequencing analysis of amplicons allowed us to verify the specificity of
methods. Clarithromycin (10 mg kg-1 twice a day) was administered in ureaplasma-positive patients
who presented clinical signs of RDS.
Results: 15/24 neonates with RDS (p < 0.001) and 4/26 without RDS were found PCR-positive for
U. urealyticum or U. parvum. Culture identification assay was positive in 5/50 newborns, three of
which with RDS. Sequencing analyses confirmed the specificity of these methods. Association of
patent ductus arteriosus with ureaplasma colonization was more statistically significant (p = 0.0004)
in patients with RDS than in those without RDS.
Conclusion: Colonization of the lower respiratory tract by Ureaplasma spp. and particularly by U.
parvum in preterm newborns was related to RDS. The routine use of molecular methods could be
useful to screen candidate babies for etiologic therapy.
Background
Respiratory distress syndrome (RDS), a major cause of
morbidity and mortality in preterm infants, is caused by
cardiopulmonary immaturity with a deficiency of sur-
factant in the alveolar space. RDS is often associated with
patent ductus arteriosus (PDA), intraventricular haemor-
rhage and chronic lung diseases which could complicate
RDS [1,2]. Among the infectious agents that colonise or
infect the genital and the lower urinary tract [3,4], Urea-
plasma urealyticum and  Mycoplasma hominis have been
linked to the development of chronic lung diseases (CLD)
[5,6] or brochopulmonary dysplasia [7,8], while their role
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in the pathogenesis of RDS remains controversial. Several
lines of evidence suggest that U. urealyticum may cause
lung injury through a number of mechanisms including
the inhibition of pulmonary surfactant by phospholipase
A2 produced by U. urealyticum and the production of
interleukins as well as of soluble intercellular adhesion
molecules [9,6].
U. urealyticum and Mycoplasma  are among the less fre-
quently diagnosed respiratory pathogens in a clinical
environment, mainly because of the lack of standardised
and specific diagnostic tests. PCR techniques have proved
useful in detecting U. urealyticum in clinical specimens
[10,11] due to time saving and the possibility of directly
identifying the mycoplasma species. In addition, studies
of genome sequencing of U. urealyticum have allowed two
different species to be distinguished, serotyped and geno-
typed as U. urealyticum (Shepard et al. 1974, species; biovar
2; serovars 2, 4, 5, 7–13) and U. parvum (Robertson et al.
2002, sp. nov.; biovar 1; serovars 1, 3, 6, 14) [12,13].
Accumulating data suggest a possible link between U. ure-
alyticum and the clinical chronic lung diseases outcome.
Recently, Kotecha and co-workers have described the col-
onization of their study patients with either biovar 1 or
biovar 2, but not both, without a different distribution
inside patient groups [6]. The role that human ureaplas-
mas could have in the pathogenesis of RDS in preterm
newborns is not completely known. The distinction of U.
urealyticum and U. parvum species could also open new
perspectives of study.
The aim of this study was to evaluate the prevalence and
the short-term outcome of perinatal U. urealyticum and U.
parvum  infections in premature infants by molecular
approaches including species-specific PCR assays, com-
pared with a test for the rapid identification of M. hominis
and Ureaplasma spp., in order to demonstrate an associa-
tion between the colonization of these microrganisms
and the development of RDS. Sequence analysis of the




Our population study included premature and full-term
newborns who were admitted within 24 h after birth to
the neonatal intensive care unit (NICU) of "G. Salvini"
Hospital in the Rho District, Milan, Italy, between Febru-
ary 2001 and January 2002. Criteria of recruitment were i)
the need for assisted ventilation with or without very low
birth weight and the gestational age < 37 weeks and ii) the
exclusion of major congenital abnormalities and of intra-
uterine transmitted infections, including TORCH, apart
from mycoplasmal and ureaplasmal infections. Ventila-
tory requirements (on days 1, 7, 14, 21 and 28 of life)
were summarized using the fractional inspired oxygen
(FiO2), as the amount of oxygen delivered to the patient
[1,7]. Mechanical ventilation was obtained by tracheal
intubation or by nasal continuous positive airways pres-
sure. Gestational age was established by the last normal
menstrual period and ultrasound examination before 20
weeks of gestation. Data of maternal risk factors (hyper-
tension, premature rupture of membranes [PROM], amni-
onitis, chorioamnionitis and antenatal steroids
administration) were obtained from clinical charts. Moth-
ers of the study children represented all socio-economic
levels.
Seven patients were excluded from the study: four,
because their gestational age was over 37 weeks, in spite
of the need for ventilatory assistance, and three, because
they did not need respiratory assistance and were trans-
ferred early to another clinic. According to recruitment cri-
teria, infants admitted in the study were classified in two
groups: group 1 included all infants with RDS (24); group
2 included newborns without RDS which needed ventila-
tory assistance by continuous positive airways pressure for
no longer than 48 hours (26). A control group repre-
sented by 20 healthy full-term newborns, born by vaginal
delivery, without a complicated course of pregnancy or
clinical signs of respiratory diseases, was included in this
study.
The infants were cared for according to the hospital ward's
general principles concerning therapy, antibiotics, and
ventilatory therapy. Patients were hospitalised until their
clinical improvement and for not less than 28 days. Writ-
ten informed consent was obtained from parents by
attending physicians before the inclusion in this study,
which was approved by the Regional Ethics Committee of
the University of Ferrara. Research was carried out accord-
ing to the Helsinki Declaration and its successive amend-
ments.
Mothers presenting PROM received i.v. amoxycillin 1 g
three times a day. Antenatal steroid treatment (betameth-
asone 12 mg twice a day) was given in 22 cases in which
preterm delivery was anticipated at less than 34 weeks of
gestation. Vaginal specimens were obtained at the time of
the patient's admission for being in labor. Cotton – swab
samples were collected from the urethra and the endocer-
vix for identification of M. hominis and Ureaplasma spp.;
the swabs were harvested in the transport medium sup-
plied by the manufacturer and analysed by a culture iden-
tification assay (Mycoplasma Duo test kit, Bio-Rad
Laboratories, Italy).
All newborns with umbilical venous catheter received i.v.
ampicillin mg 100 kg-1 plus netilmicin 2.5 mg kg-1, for atBMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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least 72 hours and until the results of cultures were avail-
able. Plasmatic dosage of netilmicine was made every 4–5
days. Echocardiographic studies were performed in each
very low birth weight infant and in patients presenting
clinical signs consistent with PDA and RDS. 11 newborns
received dexamethasone i.v. administration (0.25 mg kg-1
every 12 h for 3 days) in order to improve pulmonary
function and to prevent the development of CLD. The
shorts courses of glucocorticoids were repeated every 10
days until mechanical ventilation and oxygen-therapy
were suspended. Patients with evidence of RDS received
endotracheal treatment with natural porcine surfactant
(Curosurf, Chiesi, Italy) (200 mg kg-1 for the first dose,
100 mg kg-1 for the following doses, with a minimal inter-
val of 8 hours). Newborns that resulted positive for U. ure-
alyticum or U. parvum by microbiological or PCR analyses
received intravenous (i.v.) clarithromycin at a dosage of
10 mg kg-1 twice a day. Clinical specimens of patients with
or without clarithromycin treatment were tested before
the tracheal intubation was removed or after clinical
improvement, respectively.
2. Disease definition
RDS was defined by the presence of 2 or more of the fol-
lowing criteria: evidence of respiratory compromise
shortly after delivery (tachypnea, intercostal retractions,
expiratory grunting) [2], and a persistent oxygen require-
ment for more than 24 hours (FiO2 > 0.4), administration
of exogenous pulmonary surfactant, and/or radiographic
evidence of hyaline membrane disease [1,2,14]. Chest
radiographs were obtained as part of routine clinical care,
and their interpretation was performed by a single radiol-
ogist, who was unaware of the clinical data and culture
results. CLD was defined as the need for supplemental
oxygen at 28 days of age or the need for supplemental oxy-
gen at 36 weeks postconceptional age [15].
PDA was diagnosed by Doppler echocardiographic stud-
ies. Ibuprofen lysine (10 mg kg-1 for the first day, followed
by 5 mg kg-1 after 24 and 48 hours) was intravenously
given to infants for the treatment of PDA. After medical
treatment an echocardiographic study was performed to
confirm that the ductus arteriosus was closed [16]. In one
patient, after the failure of medical treatment with ibupro-
fen and then with indomethacin, surgical ligation was
performed.
3. Clinical specimens
Endotracheal aspirates (TA) or nasopharyngeal fluids
(NF), from intubated or non-intubated infants, respec-
tively, and serum samples were collected soon after the
birth, within the first 12 hours of life and before adminis-
tration of surfactant or antibiotics, in order to exclude
nosocomial transmission of infectious agents and to
avoid any possible interference with laboratory findings.
After mechanical suction, TA and NF, collected by cathe-
ters, were inoculated in 2 mL of an adapted transport
media supplied by the manufacturer and then analysed by
culture identification assay. 40–50 μL of each sample
diluted in the transport medium were placed in plates
containing a specific medium to identify U. urealyticum/U.
parvum and M. hominis, distinguished by urea or arginine
utilization, respectively. Blood samples were inoculated
into a blood-culture bottle for either aerobic or anaerobic
bacteria (1 mL) and incubated at 37°C for 24 and 48
hours. Positive cultures were further inoculated into spe-
cific media to identify the bacteria species. Sterile cotton
swabs were rubbed over the infant's posterior pharynx,
over the ear and rectum and cultured for conventional
bacteria twice weekly until discharge, as part of routine
surveillance in the NICU.
4. Polymerase chain reaction
We employed the common careful procedures (aliquoting
autoclaved reagents, UV-irradiation treatment for surface
laboratory benches, filter-tips and adding DNA last) in
order to avoid the risk of contamination by DNA or PCR
product carryover.
Each TA or NF specimen (approximately 5 to 10 mL) was
collected in ureaplasma broth, containing urea, ampicil-
lin 66 mg mL-1 and foetal calf serum 20% (A3 medium),
and in M. hominis broth, containing arginine, ampicillin
66 mg mL-1 and foetal calf serum 20% (BDA medium). 2
mL of each sample was then added to an equal volume of
phosphate buffered saline (PBS, pH 7.2) and centrifuged
at 12,000 g for 15 min. A portion of pellet was resus-
pended in 1 mL A3 or BDA medium and stored until
required for PCR evaluation. Sample lysis was done as
previously described on 200 μL of each sample. Before
PCR, 2 μL direct and tenfold dilutions of each sample
were amplified in order to test that lysis had occurred and
to identify the possible inhibition of amplification due to
the presence of contaminants in the sample [17]. Speci-
mens were formerly screened by Mycoplasma spp. and Ure-
aplasma spp. specific primers (MGSO/GPO1, 717 bp) and
then by species-specific primer pairs for U. urealyticum and
U. parvum, and M. hominis. In order to investigate other
most common human mycoplasmas, PCR assaywas used
to search for M. pneumoniae and M. genitalium. Genus and
species-specific mycoplasma oligonucleotide primers
(Genset, France) were deduced from either the conserved
or variable 16S RNA regions, while UU3, UU4 and UU5
U. urealyticum primers were also obtained from the
sequence of urease gene (table 1) [11,17]. PCR assay to
distinguish U. urealyticum and U. parvum was performed
by employing oligonucleotides previously described [18].
Amplification conditions for the different PCR systems are
summarized in table 1. MGSO/RNA5 primer pairs were
less specific and more sensitive than GPO1/MGSO. A trueBMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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positivity was considered if obtained with both pairs of
primers. The thermal cycler apparatus was a PCR-Express
PCYL001 (Hybaid, UK).
20  μL of amplified products were electrophoresed on
0.8% agarose gels in TAE buffer together with a number of
positive and negative controls and bands were visualised
by ethidium bromide staining. Sensitivity of the PCR
assay was defined at 10 fg of DNA corresponding to 10 –
15 mycoplasmas mL-1 or 10 CFU.
5. Sequence analysis
The amplification products from TA and NF that resulted
Mycoplasma  spp. or Ureaplasma  spp. positive were ana-
lysed by cycle sequencing (Ampli-Cycle Sequencing Kit,
Perkin Elmer, CA, USA), in order to verify the specificity
of employed primers and to identify the serovars of the
Ureaplasma  species. PCR products were purified from
amplification reaction mixture and cycle sequencing was
performed according to the manufacturer's instructions
(Redivue™, Amersham Pharmacia Biotech, England).
In order to confirm the accuracy of the sequencing analy-
sis, the same PCR products were also sequenced by an ABI
PRISM® 377 DNA Sequencer. The closest matches for the
sequences obtained were determined by BLAST searches
[19]. Serovars of U. parvum or U. urealyticum were deter-
mined by identities detected with the BLAST search in the
GenBank.
6. Statistical analysis
The medians for the gestational age, birth weight, days of
hospitalisation, Apgar score and hours of mechanical ven-
tilation were given. Comparison between frequencies of
clinical parameters and molecular analyses in the exam-
ined groups was performed with Fisher's exact test. A
logistic regression was made, correlating the independent
variables, to calculate the statistical significance by maxi-
mum likelihood χ2-analysis. P-values < 0.05 were consid-
ered significant. STATISTICA software was used.
Results
Fifty patients were admitted in the study, 24 in group 1
and 26 in group 2. The most relevant clinical features of
patients are shown in table 2. Two pairs of twins were
included in the study population, one born by vaginal
delivery and the other by Caesarean delivery. One baby in
each pair showed typical clinical signs of RDS and was
therefore included in group 1.
Culture identification assays showed five (10%) positive
cases out of 50 patients, three of which with RDS, com-
pared to 19/50 (38%; p < 0.05) obtained by PCR tech-
nique. Culture identification assays resulted negative for
M. hominis. Vaginal cotton-swab specimens resulted posi-
tive by culture identification assay for Ureaplasma  spp.
either in 12 mothers of newborns with RDS or in 6 moth-
ers of babies without RDS. 12/18 positive women gave
birth to a newborn PCR positive for U. urealyticum or U.
parvum, and 2/18 gave birth to a pair of twins.
Genus- and species-specific PCR demonstrated U. urealyti-
cum and U. parvum DNA in 14/24 TA and 1/24 serum
from the patients (62.5%; χ2-test: p = 0.0004) in group 1,
and in 4/26 NF (15.4%) from the patients in group 2 (fig-
ure 1). U. parvum specific-PCR with pairs of primers U3/
P6 and U8/P6 resulted positive in 10/15 patients in group
1. In particular, the patient with RDS and the identifica-
tion of U. parvum DNA, died on the 8th day of extrauterine
life, due to complicated pneumothorax, intraventricular
haemorrhage (grade III) and Staphylococcus epidermidis
sepsis. This baby's respiratory secretions were not availa-
ble. Of the two pairs of twins, two patients with RDS had
a positive PCR for U. parvum only. No amplification signal
Table 1: Oligonucleotides employed as primers in PCR assays for detection of Mycoplasma and Ureaplasma species.
Species Primers name (sense/antisense) Gene targets, amplicon size (bp) Conditions of n-PCR amplification
Mycoplasma spp. [17] RNA5 (agagtttgatcctggctcagga)/MGSO 
(tgcaccatctgtcactctgttaacctc)
16S rRNA, 1005 1 cycle of 15 min. at 95°C; 30 cycles of 30 sec. at 
95°C, 90 sec. at 58°C, 90 sec. plus 1 sec./cycle at 
72°C; final extension of 10 min. at 72°C.
Mycoplasma spp. [17] GPO1(actcctacgggaggcagcagta)/MGSO 
(tgcaccatctgtcactctgttaacctc)
16S rRNA,717
M. pneumoniae + M. genitalium [17] PNEU+GEN (cctgcaagggttcgttattt)/MGSO 
(tgcaccatctgtcactctgttaacctc)
16S rRNA,851
M. hominis [17] HOM (tgaaaggcgctgtaaggcgc)/UNI- 
(taatcctgtttgctccccac)
16S rRNA,589
U. urealyticum + U. parvum [11] UU3 (gatggtaagttagttgctgag)/UU4 
(acgacgtccataagcaact)
Urease, 456 0.8 μM of each primer, MgCl2 1.5 mM; dNTP 0.2 
mM; Taq DNA polymerase 1U/50 μl.
U. urealyticum + U. parvum [11] UU5 (caatctgctcgtgaagtattac)/UU4 
(acgacgtccataagcaact)
Urease, 429
U. urealyticum [18] U8 (gaagatgtagaaagtcgcgtttgc)/P6 
(ggtagggataccttgttacgact)
16S rRNA, 1312 1 cycle of 5 min. at 95°C; 30 cycles of 30 sec. at 
95°C, 30 sec. at 58°C, 2 min 30 sec. at 72°C.
U. parvum [18] U3 (tagaagtcgctctttgtgg)/P6 
(ggtagggataccttgttacgact)
16S rRNA, 1305 1 μM of each primer, MgCl2 1.5 mM; dNTP 0.2 
mM; Taq DNA polymerase 1.25U/50 μl.BMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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was found for other mycoplasmas. NF samples from the
newborns of the control group (n. 20) resulted negative
with both culture identification and PCR assays.
One fact of interest is that a female with low birth weight
and clinical signs of RDS, was admitted to NICU on two
different occasions. During the first admission (45 days),
NF samples resulted both culture identification assay and
PCR negative. Fifteen days after discharge, she was admit-
ted to NICU a 2nd time, because of hypothermia and dys-
pnea. Ventilatory assistance was started because of a fine
miliary mottling through the lungs at RX with an air bron-
chogram and a FiO2 at 0.35. NF samples collected during
this re-admission, were PCR positive for U. parvum.
The detection rate of U. urealyticum and U. parvum was
higher in TA of patients that received surfactant than in
specimens of those not treated, with a high ureaplasmal
positivity in the patients of group 1 (100%; χ2-test: p =
0.004). Moreover, there was a significant statistical differ-
ence in PCR results when compared with mechanical ven-
tilatory requirements (100%; χ2-test: p = 0.004). The
incidence of PDA was higher and statistically significant in
patients in group 1, in comparison with those of group 2
(χ2-test: p = 0.04) (table 2), with a high U. urealyticum or
U. parvum-PCR positivity detection rate which was higher
in group 1 (n = 14; 93,3%) than in group 2 (n = 1; 25%).
Gestational age and birth weight were not statistically sig-
nificant for small amount of data.
BLAST sequencing analyses showed that amplified frag-
ments of 456 bp (UU3/UU4) and 429 bp (UU4/UU5)
aligned in the GenBank database with sequences of urease
gene of U. urealyticum (GenBank AE002140) and U. par-
vum (GenBank AF0875729) (figure 2). DNA sequences of
the 456 bp and 429 bp PCR amplicons from the urease
gene of the isolates were 93.1–99.7 % identical to urease
gene sequences for the different ureaplasma type strains.
A more specific analysis by pairing of amplification
sequences, confirmed that the amplicons were consistent
with U. parvum in 10/15 patients, and U. urealyticum in 5/
15 patients in group 1, and U. urealyticum in 4/4 patients
in group 2 (χ2-test: p = 0.004). BLAST alignment of the
16S rRNA amplicons, obtained by PCR with U3/P6 or U8/
P6 primers, confirmed the distinction of species and sero-
vars evidenced by urease gene amplification (U. parvum:
GenBank AF002112 [figure 3]; U. urealyticum: GenBank
AF073455, AF073454 [figure 4]). All serovars of U. par-
vum were represented and serovars 2, 4, 8 and 13 were
within the U. urealyticum species.
Patients that had a positive PCR assay for U. urealyticum
and U. parvum were treated with intravenous clarithro-
mycin at a dosage of 10 mg kg-1 twice a day for ten days
or until clinical improvement. These patients did improve
clinically and respiratory secretions did result negative
with laboratory assays. PCR positive TA or NF specimens
were PCR negative after treatment. The follow-up of new-
borns showed clinical and laboratory signs for CLD after
Table 2: Characteristics of the examined population stratified by group of patients with or without RDS.
GROUP 1 (n. 24) GROUP 2 (n. 26) §
U. urealyticum positive 
PCR 
(n. 5)












Culture identification assay positivity (%) 1 (20) 2 (20) 0 2 (50) 0
Median gestational age, weeks (range) 35+3 (28; 37+5) 31+2 (23+2; 35+2) 32+5 (27+2; 37) 32 (30+5; 34) 32+4 (30; 37)
Median birthweight, g (range) 2530 (1070–3000) 1660 (720–2950) 1930 (1030–2690) 1340 (1140–2260) 1635 (750–3580)
Median days of hospitalisation 30 (22–60) 33 (7*–60) 22 (10–70) 32 (18–42) 23 (4–60)
Median Apgar score, 1' (range) 8 (6–10) 8 (5–10) 4.5 (1–10) 9.5 (8–10) 7 (1–10)
Median Apgar score, 5' (range) 9 (8–10) 9.5 (8–10) 10 (3–10) 9.5 (9–10) 10 (6–10)
Gender, male (%) 1 (20) 3 (30) 2 (22.2) 3 (75) 6 (27.3)
Antenatal steroids (%) 2 (40) 8 (80) 2 (22.2) 3 (75) 8 (36.4)
Antenatal ampicillin (%) 2 (40) 7 (70) 3 (33.3) 2 (50) 6 (27.3)
PROM > 12 hours (%) 0 2 (20) 0 1 (25) 4 (18.2)
Caesarean delivery (%) 3 (60) 5 (50) 6 (66.7) 2(50) 13 (59.1)
Blood culture positive (%) 1 (6.7) 0 1 (11.1) 0 0
Surfactant (%) 5 (100) 10 (100) 5 (55.6) 0 0
PDA (%) 4 (80) 10 (100) 5 (55.6) 1 (25) 7 (31.8)
Neonatal dexamethasone (%) 6 (40) 2 (22.2) 1 (25) 2 (9.1)
Mechanical ventilatory requirement (%), 
median duration (hours)
5 (100), 60.5 9 (100), 72 6 (66.7), 72 3 (75), 60 4 (18.2), 48
FiO2 > 0.40 (range) 5 (0.40) 9 (0.40–1.00) 5 (0.40–0.90) 0 0
CLD at 28 days (%) 1 (20) 1 (10) 0 1 (25) 0
CLD at 36 weeks (%) 0 0 0 0 0
* patient died; § no patient resulted U. parvum PCR positive in this group.BMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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28 days, in two patients in group 1, who resulted PCR pos-
itive for U. parvum and U. urealyticum, respectively, and
in one patient in group 2, PCR positive for U. urealyticum
only.
Discussion
The aim of this study was to investigate the colonization
of the respiratory tract of preterm newborns by U. urealyti-
cum, U. parvum and M. hominis using an in-house PCR and
to prove a possible association between RDS and urea-
plasma infection. U. urealyticum and  M. hominis were
identified more frequently in respiratory secretions and
less frequently in cerebrospinal fluid and blood speci-
mens of preterm newborns with pneumonia, meningitis
and sepsis, respectively [12,20]. A number of studies
attempted to relate U. urealyticum colonization to the
development of respiratory diseases in high risk newborns
(gestational age < 28 weeks) and mostly with CLD, but the
effective role of U. urealyticum and U. parvum in the patho-
genesis of RDS when associated with prematurity remains
controversial. A recent study showed an association of res-
piratory failure due to RDS with U. urealyticum coloniza-
tion on bronchoalveolar lavage samples [6] using specific
primers for U. urealyticum urease-gene, different from
those employed by us.
After an accurate search of the biomedical literature by
PubMed database [19], our study was the first work in
which a PCR method was applied to distinguish U. urea-
lyticum  from  U. parvum by species – specific primers
directly on clinical respiratory samples of premature
infants. Using this method, U. parvum was detected only
in TA of patients with RDS and U. urealyticum in respira-
tory samples of both groups of patients, but no sample
was colonized with both Ureaplasma spp. A significantly
high difference in PCR results for U. urealyticum and U.
parvum  was detected especially in TA of newborns in
group 1 that received surfactant by endotracheal instilla-
tion. A previous study supported the efficacy of exogenous
surfactant administration in premature infants with RDS
Agarose gel electrophoresis of urease gene PCR Figure 1
Agarose gel electrophoresis of urease gene PCR. 20 μL of amplified products for the urease gene were electrophoresed 
on 0.8% agarose gel in TAE buffer (40 mM tris-acetate, 1 mM EDTA, pH 8). A) Lanes 1–14: PCR results of TA samples of new-
borns with RDS; lanes 15–16: U. urealyticum and U. parvum PCR positive control; lanes 17 and 24: 100 bp ladder; lanes 18–23 
PCR results of TA or NF samples of newborns without RDS. B: PCR negativity for Ureaplasma spp. of respiratory secretions 
from the control group; lane 13: 100 bp ladder; lanes 19–20: U. urealyticum and U. parvum PCR positive control.BMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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BLAST sequence analysis of Ureaplasma spp. ureasegene amplicons Figure 2
BLAST sequence analysis of Ureaplasma spp. ureasegene amplicons. BLAST sequence analysis of urease gene ampli-
fied fragments of U. urealyticum (GenBank AE002140) and U. parvum (GenBank AF085729) in two different respiratory speci-
mens: sample SR1 (A) resulted identical to U. parvum and sample SR42 (B) resulted more identical to U. urealyticum than U. 
parvum. Nucleotide differences between sequences of two species are shown.
1_21496   35     agaatactaatgcactatttgtttcaaataagtggaaatgtgatccaacttggataggac 94
AF085729  684    ............................................................ 625
1_21496   95     ggtcaccagtatttttaatgctgattacttttgcttctctaccttcgttcatcacaattt 154
AF085729  624    ............................................................ 565
1_21496   155    cgccttcagcgaagttaattgctcctggtactaatttacctggagtgaattgatttga-t 213
AF085729  564    ..........................................................-. 506
1_21496  214    gatcctgacatataatcattatctccttataaaattaaaattgattttacgaattgtaaa 273
AF085729 505    ............................................................ 446
1_21496  274    aattatttgtaaatttagtaccatctgggaaagtaacttcaacttggattataccaacca 333
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AF085729 410                 ............................................... 364
1_21496  334    ttgtatctacaccttccataacttgatcaacacgtaatacttcacgagcagattg  388
AF085729 363    .......................................................  309
1_25064  38     aaaatctaatgcctattcacttcaaacaagtgaaaatgtgatccaacttgtataggacgg 97
AE002140 3321               ................................................ 3368
AF085729 662                        ......t.....g.................g......... 623
1_25064  98     tccccagtatttttaatactaattacttttgcctctctaccttcattcatcacaatttca 157
AE002140 3369   ............................................................ 3428
AF085729 622    ..a..............g..g...........t...........g..............g 563
1_25064  158    ccactagcgaaattaattgcccctggtactaatttacctggactaaattgacttga-tga 216
AE002140 3429   ........................................................-... 3487
AF085729 562    ..ttc......g........t.....................g.g......t....-... 504
1_25064  217    tcctgacatataatcattatctccttttataaaaaaattttacgaattgtaaatgttatt 276
AE002140 3488   ............................................................ 3547
AF085729 461                                         ................aa..... 439
AF085729 503    ..........................                                   478
1_25064  277    tgtaaattggatcgtgtacagaaactagtttagtaccatcagggaaagtaacttcaactt 336
AE002140 3548   ............................................................ 3607
AF085729 438    ..........gct...........................t................... 379
1_25064  337    gaattatactaaccattgtatctacaccttccataacttgatcaacacgtaatacttcac 396
AE002140 3608   ............................................................ 3667
AF085729 378    .g.......c.................................................. 319
1_25064  397    gagcaga  403
AE002140  3668   .......  3674
B
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BLAST sequence analysis of Ureaplasma parvum 16SrRNA amplicons Figure 3
BLAST sequence analysis of Ureaplasma parvum 16SrRNA amplicons. BLAST sequence analysis of 16S rRNA gene 
amplified fragments of U. parvum (GenBank AF002112) employing U3/P6 primers, in the sample SR1 resulted identical to U. 
parvum. Nucleotide differences between sequences of two species are shown.
query    1     caatgacgcgtagctgtactgagaggtagaacagccacaatgggactgagacacggccca  60
AF002112 432   ............................................................  491
query    61    tactcctacgggaggcagcagtagggaatttttcacaatgggcgcaagccttatgaagca  120
AF002112 492   ............................................................  551
query    121   atgccgcgtgaacgatgaaggtcttatagattgtaaagttcttttatatgggaagaaacg  180
AF002112 552   ............................................................  611
query    181   ctaagataggaaatgattttagtttgactgtaccatttgaataagtatcggctaactatg  240
AF002112 612   ............................................................  671
query    241   tgccagcagccgcggtaatacataggatgcaagcgttatccggatttactgggcgtaaaa  300
AF002112 672   ............................................................  731
query    301   cgagcgcaggcgggtttgtaagtttggtattaaatctagatgcttaacgtctagctgtat  360
AF002112 732   ............................................................  791
query    361   caaaaactgtaaacctagagtgtagtagggagttggggaactccatgtggagcggtaaaa  420
AF002112 792   ............................................................  851
query    421   tgcgtagatatatggaagaacaccggtggcgaaggcgccaacttggactatcactgacgc  480
AF002112 852   ............................................................  911
query    481   ttaggctcgaaagtgtggggagcaaataggattagataccctagtagtccacaccgtaaa  540
AF002112 912   ............................................................  971
query    541   cgatcatcattaaatgtcggcccgaatgggtcggtgttgtagctaacgcattaaatgatg  600
AF002112 972   ............................................................  1031
query    601   tgcctgggtagtacattcgcaagaatgaaactcaaacggaattgacggggacccgcacaa  660
AF002112 1032  ............................................................  1091
query    661   gtggtggagcatgttgcttaatttgacaatacacgtagaaccttacctaggtttgacatc  720
AF002112 1092  ............................................................  1151
query    721   tattgcgatgctatagaaatatagttgaggttaacaatatgacaggtggtgcatggttgt  780
AF002112 1152  ............................................................  1211
query    781   cgtcagctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaacccctttcgtt  840
AF002112 1212  ............................................................  1271
query    841   agttacttttctagcgatactgctaccgcaaggtagaggaaggtggggatgacgtcaaat  900
AF002112 1272  ............................................................  1331
query    901   catcatgccccttatatctagggctgcaaacgtgctacaatggctaatacaaactgctgc  960
AF002112 1332  ............................................................  1391
query    961   aaaatcgtaagatgaagcgaaacagaaaaagttagtctcagttcggatagagggctgcaa  1020
AF002112 1392  ............................................................  1451
query    1021  ttcgtcctcttgaagttggaatcactagtaatcgcgaatcagacatgtcgcggtgaatac  1080
AF002112 1452  ............................................................  1511
query    1081  gttctcgggtcttgtacacaccgcccgtcaaactatgggagctggtaatat  1131
AF002112 1512  ...................................................  1562BMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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BLAST sequence analysis of Ureaplasma urealyticum 16S rRNA amplicons Figure 4
BLAST sequence analysis of Ureaplasma urealyticum 16S rRNA amplicons. BLAST sequence analysis of 16S rRNA 
gene amplified fragments of U. urealyticum (GenBank AF073455, AF073454) employing U8/P6 primers in the sample SR42 
resulted identical to U. urealyticum. Nucleotide differences between sequences of two species are shown.
query    1     atgacgcgtagctgtactgagaggtagaacagccacaatgggactgagacacggcccata  60
AF073455 244   ............................................................  303
AF073454 244   ............................................................  303
query    61    ctcctacgggaggcagcagtagggaatttttcacaatgggcgcaagccttatgaagcaat  120
AF073455 304   ............................................................  363
AF073454 304   ............................................................  363
query    121   gccgcgtgaacgatgaaggtcttatagattgtaaagttcttttatatgggaagaaacgct  180
AF073455 364   ............................................................  423
AF073454 364   ............................................................  423
query    181   aagataggaaatgattttagtttgactgtaccatttgaataagtatcggctaactatgtg  240
AF073455 424   ............................................................  483
AF073454 424   ............................................................  483
query    241   ccagcagccgcggtaatacataggatgcaagcgttatccggatttactgggcgtaaaacg  300
AF073455 484   ............................................................  543
AF073454 484   ............................................................  543
query    301   agcgcaggcgggtttgtaagtttggtattaaatctagatgcttaacgtctagctgtatca  360
AF073455 544   ............................................................  603
AF073454 544   ............................................................  603
query    361   aaaactgtaaacctagagtgtagtagggagttggggaactccatgtggagcggtaaaatg  420
AF073455 604   ............................................................  663
AF073454 604   ............................................................  663
query    421   cgtagatatatggaagaacaccggtggcgaaggcgccaacttggactatcactgacgctt  480
AF073455 664   ............................................................  723
AF073454 664   ............................................................  723
query    481   aggctcgaaagtgtggggagcaaataggattagataccctagtagtccacaccgtaaacg  540
AF073455 724   ............................................................  783
AF073454 724   ............................................................  783
query    541   atcatcattaaatgtcggctcgaacgagtcggtgttgtagctaacgcattaaatgatgtg  600
AF073455 784   ............................................................  843
AF073454 784   ............................................................  843
query    601   cctgggtagtacattcgcaagaatgaaactcaaacggaattgacggggacccgcacaagt  660
AF073455 844   ............................................................  903
AF073454 844   ............................................................  903
query    661   ggtggagcatgttgcttaatttgacaatacacgtagaaccttacctaggtttgacatcta  720
AF073455 904   ............................................................  963
AF073454 904   ............................................................  963
query    721   ttgcgacgctatagaaatatagttgaggttaacaatatgacaggtggtgcatggttgtcg  780
AF073455 964   ............................................................  1023
AF073454 964   ............................................................  1023
query    781   tcagctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaacccctttcgttag  840
AF073455 1024  ............................................................  1083
AF073454 1024  ............................................................  1083
query    841   ttgcttttctagcgatactgctaccgcaaggtagaggaaggtggggatgacgtcaaatca  900
AF073455 1084  ............................................................  1143
AF073454 1084  ............................................................  1143
query    901   tcatgccccttatatctagggctgcaaacgtgctacaatggctaatacaaactgctgcaa  960
AF073455 1144  ............................................................  1203
AF073454 1144  ............................................................  1203
query    961   aatcgtaagatgaagcgaaacagaaaaagttagtctcagttcggatagagggctgcaatt  1020
AF073455 1204  ............................................................  1263
AF073454 1204  ............................................................  1263
query     1021  cgccctcttgaagttggaatcactagtaatcgcgaatcagacatgtcgcggtg  1073
AF073455  1264  .....................................................  1316
AF073454  1264  .....................................................  1316BMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
Page 10 of 12
(page number not for citation purposes)
[15] and a recent finding, obtained using a culture based
method, showed that 73% of preterm neonates colonized
from U. urealyticum and U. parvum had RDS [21]. Another
study has shown a prevalence (76–81%) of U. parvum in
amniotic fluid from preterm complicated gestation [22].
Our findings suggested that U. parvum may play a more
effective role in the pathogenesis of RDS than U. urealyti-
cum.
Although in our study antibiotic therapy was restricted to
newborns that resulted PCR positive for Ureaplasma spp.
without a placebo-treated control group, the improve-
ment of the clinical outcome observed in patients after
clarithromycin treatment may be a further suggestion that
the colonization of the respiratory tract by U. urealyticum
and U. parvum could be considered an important factor
that contributes to acute lung injury. Moreover, as shown
by culture and PCR DNA detection, this treatment led to
eradication of Ureaplasma spp. in TAs as well as in NF
specimens, before the removal of tracheal intubation.
The PCR assay showed a greater sensitivity than culture
identification assay in detecting Ureaplasma spp. At the
time the samples were collected, culture identification
assay, recently approved only for testing genital specimens
with a good sensitivity, was also applied to respiratory
secretions.
A body of evidence suggests that Ureaplasma spp. infec-
tions, as well as genital infections, are linked to compli-
cated pregnancy (PROM, chorioamnionitis, Caesarean
delivery or funisitis) or neonatal outcome (low birth
weight, gestational age < 37 weeks, neonatal sepsis, CLD,
BPD) [23,24] but infants born premature by mothers with
chorioamnionitis did not develop RDS despite the higher
association of ureaplasma biovar 1 (U. parvum) colonisa-
tion with CLD [15]. As regards the clinical parameters of
the pregnancy, apart from longer hospitalisation in new-
borns found positive for ureaplasma, compared with
those negative with both methods (table 2), we did not
find statistical differences between the two groups for
small amount of our data, according to previous study
[22]. Our study was specifically focused on infants with
RDS who did not have any clinical or laboratory evidence
of infection at birth; thus suggesting that U. urealyticum or
U. parvum must be considered important cofactors to the
development or initiation of acute lung injury, according
to other studies [6,25,26]. Interestingly, U. parvum PCR
positivity was detected in TAs of twins with RDS (one of
each pair of twins enrolled in this study) but not in the
respective siblings without RDS. These data could indicate
that ureaplasmal infection may be a possible causative
factor in the pathogenesis of RDS. No link with the
method of delivery as a favourable factor was found,
although our data are not statistically significant.
A further consideration concerns PDA and ureaplasma
colonization. Statistical analysis has shown that the inci-
dence of PDA in the two groups of patients was weakly sig-
nificant but a greater statistical significance was observed
in patients with PDA and RDS that resulted positive for U.
urealyticum or U. parvum. These data were consistent with
a previous study which has demonstrated that PDA may
be considered a pathology influencing respiratory mor-
bidity [27]. These findings contributed to providing fur-
ther evidence that U. parvum and  U. urealyticum
colonizations could complicate the clinical course of RDS
in preterm infants with PDA.
Another finding of this study was the positivity of U. par-
vum in the female patient during the 2nd admittance, at
two months of extrauterine life, compared with the PCR-
negativity found at the 1st admission. We suppose that
ureaplasmal load of the first NF sample was very low, so
that U. parvum was undetectable. Its persistence in the
lower respiratory tract following the first discharge as
demonstrated by PCR positivity, supported a replication
of ureaplasmas which may lead to histological lung dam-
age, as shown by the clinical picture of RDS. In this case,
our data agreed with those of Castro-Alcaraz and co-work-
ers that described three patterns of U. urealyticum coloni-
zation of preterm infants developing a CLD: persistent
positive, transient and late transient colonization [28].
The improvement of the clinical picture after clarithromi-
cyn treatment supported this hypothesis.
The role of the immune response in determining RDS is
not secondary. In vitro and in vivo studies demonstrated a
release of proinflammatory cytokines (TNF-α, IL-1β, IL-6)
and G-CSF and GM-CSF from lymphomonocyte and alve-
olar cells, respectively, stimulated by mycoplasma- and
ureaplasma-derived lipoproteins [29,30]. Biochemical
mechanisms, such as the inhibition of pulmonary sur-
factant production by phopspholipase A2 [9] may result in
acute lung damage.
Conclusion
U. parvum more than U. urealyticum were found by PCR in
respiratory secretions of preterm newborns with RDS,
indicating a possible role of these Mollicutes in the patho-
genesis of RDS. Our findings support the evidence that
PCR could be a highly sensitive and specific technique for
detecting Ureaplasma and for distinguishing U. urealyticum
from U. parvum directly in clinical specimens, suggesting
that the described PCR methods could be considered as a
possible true "gold standard", because of the selection of
primers with wide specificity that react with the DNA of
Ureaplasma or Mycoplasma derived from target sequences
in the highly conserved regions of the genes. The routine
use of this technique for NICU patients could have a role
in more accurately diagnosing infection by U. parvum andBMC Infectious Diseases 2006, 6:166 http://www.biomedcentral.com/1471-2334/6/166
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U. urealyticum, especially in newborns at risk of develop-
ing RDS.
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